AbbVie stock nudges higher after Canada clears Maviret — what ABBV investors watch next
New York, January 6, 2026, 12:36 PM ET — Regular session AbbVie shares rose about 0.5% to $221.18 in midday trading on Tuesday after the drugmaker said Health Canada approved its hepatitis C therapy Maviret (glecaprevir/pibrentasvir) for acute and chronic infections. The clearance expands use of an eight-week oral regimen and supports “treat early” strategies aimed at cutting transmission by starting therapy as soon as patients are diagnosed. That matters as investors look for steadier growth drivers and pipeline progress ahead of key investor events this month. AbbVie said Maviret is now approved in Canada for adults and children aged